Navigation Links
OncoGenex Technologies Announces Phase II Data of OGX-011 in,Metastatic Breast Cancer at American Association for Cancer,Research 2007 Annual Meeting

VANCOUVER, April 17, 2007 /PRNewswire/ - OncoGenex Technologies Inc. announced today data from a Phase II clinical trial of OGX-011 in combination with docetaxel in patients with metastatic breast cancer (MBC). Data was presented by the National Cancer Institute of Canada - Clinical Trials Group at the American Association for Cancer Research 2007 Annual Meeting in Los Angeles, Calif.

    Investigators concluded:

        -  Of the 15 patients treated, five patients (33.3 percent) showed a

           partial response and nine patients (60 percent) showed disease

           stabilization

        -  Of the nine patients reported with stable disease, tumor reduction

           ranged from approximately eight to 28 percent and disease

           stabilization was sustained for a median of 9.3 months

        -  Only one patient advanced to progressive disease

        -  While patient monitoring is ongoing, the median progression free

           survival for all patients was eight months and the median time for

           survival has not yet been reached

        -  Clinical activity was seen for the combination of OGX-011 and

           docetaxel in this generally pre-treated group of patients with

           MBC, but did not meet the pre-determined criteria of six or more

           patients achieving tumour size reductions exceeding 30 percent

           required to expand the trial into a second stage of accrual

        -  Serum clusterin levels fell on treatment in most patients, and

           there was no statistical correlation between changes from baseline

           in clusterin levels and objective tumor response

"Taxanes represent an active class of chemotherapeutic agents currently used in the treatment of breast cancer, however the majority of patients will eventually develop resistance to the therapies," said Dr. Stephen Chia, Principal Investigator for this study and Medical Oncologist at the BC Cancer Agency. "The finding that all but one patient showed some degree of clinical benefit and the median duration of disease stabilization exceeded nine months is of interest in this small study."

"We are encouraged by the conclusion made by the investigators that the combination of OGX-011 and docetaxel has activity in this patient population and by the very low incidence of progressive disease," said Scott Cormack, president and CEO of OncoGenex. "As provided in our previous guidance, these data together with the data from our other Phase II programs in prostate cancer and non-small cell lung cancer, scheduled to be released later this year, will be considered in our planning for subsequent studies, including pivotal trials."

The primary objective of this study was to assess the objective response rates (reduction in tumor size) when OGX-011 is combined with docetaxel in patients with metastatic or locally recurrent breast cancer. Secondary endpoints included estimation of time to disease progression, overall survival and the effect of OGX-011 on serum clusterin.

Fifteen patients were enrolled and all were evaluable for toxicity and response. A median of six treatment cycles were delivered. Grade 3 adverse events commonly associated with chemotherapy alone included: fatigue (33 percent), vomiting (13 percent), edema (13 percent), arthralgias (13 percent) and dyspnea (13 percent). Five patients experienced febrile neutropenia. Investigators concluded that OGX-011 is well tolerated in combination with docetaxel.

Women with measurable metastatic breast cancer and no more than one previous chemotherapy regimen for MBC were eligible for this study. OGX-011 was delivered three times at 640 mg intravenously as a loading phase prior to initiating chemotherapy. The loading phase was followed by a weekly dose of 640 mg of OGX-011 in combination with 75 mg/m2 of docetaxel. Response was evaluated following every s econd cycle.

OGX-011 is designed to specifically inhibit the production of the cell-survival protein, clusterin. Clusterin production is associated with treatment resistance in many cancers and in response to various cancer treatments, including hormone ablation therapy, chemotherapy and radiation therapy. Preclinical studies have shown that inhibition of clusterin can disable the tumor cell's adaptive defences, render the tumor cells susceptible to attack with a variety of cancer therapies, including chemotherapy, and facilitate tumor cell death. OncoGenex is developing OGX-011 in collaboration with Isis Pharmaceuticals Inc.

The study was sponsored by the National Cancer Institute of Canada - Clinical Trials Group with support provided by OncoGenex Technologies Inc.

About OncoGenex

OncoGenex is committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex currently has three product candidates in development: OGX-011, OGX-427 and OGX-225. These product candidates are designed to selectively inhibit the production of proteins that are associated with treatment resistance and that are over-produced in response to a variety of cancer treatments. OncoGenex' aim in targeting these particular proteins is to disable the tumor cells' adaptive defenses, render the tumor cells susceptible to attack with a variety of cancer therapies including chemotherapy, and facilitate tumor cell death. More information on OncoGenex and the company's pipeline is available at www.oncogenex.ca.

CONTACT: OncoGenex Contact: Scott Cormack, President & CEO, (604) 630-5400; Media Contact: Jason Spark, Porter Novelli Life Sciences, (619) 849-6005

CONTACT: OncoGenex Contact: Scott Cormack, President & CEO, (604)630-5400; Media Contact: Jason Spark, Porter Novelli Life Sciences, (619)849-6005

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. OncoGenex and Isis Announce OGX-011 Data to be Presented at ASCO
2. Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
3. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
4. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
5. Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction
6. Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at 20th International Conference on Antiviral Research Meeting
7. Micell Technologies Presents Data on Novel Drug-Eluting Stents
8. AVAX Technologies Presents Results of Phase I-II M-Vax Trial at Annual Meeting of American Association for Cancer Research
9. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/19/2017)... 2017   ZirMed Inc ., a recognized leader in ... it has been ranked #1 by its users for the ... 2017 User Survey. ZirMed was recognized as the top-ranked end-to-end ... medical centers over 200 beds and holds one of the ... survey history. ...
(Date:9/12/2017)... Sept. 12, 2017  Consumer reviews on the independent review site ... the number one company for hearing aids, ranking it higher than ... brands. ... #1 by Consumers For Hearing Aids ... Hearing is an online store that provides high performance, state-of-the-art, German-engineered ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... named one of Michigan’s 2017 Best and Brightest in Wellness® by Best and ... Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the United States, single-family ... some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average ... extremely low property-tax rates, which contributes to the relatively lower cost of living ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Dining at the University of California Berkeley, and other leading institutions in announcing ... buying power of institutions to change the way animals are raised for food. ...
(Date:10/12/2017)... Antonio, Texas (PRWEB) , ... October 12, 2017 ... ... device and biologics manufacturer, has expanded its executive staff with the addition of ... , In this role, Slott will develop the national distribution and sales network, ...
Breaking Medicine News(10 mins):